See more : Saksoft Limited (SAKSOFT.NS) Income Statement Analysis – Financial Results
Complete financial analysis of ShockWave Medical, Inc. (SWAV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ShockWave Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Worksport Ltd. (WKSPW) Income Statement Analysis – Financial Results
- Dr. Ing. h.c. F. Porsche AG (DRPRY) Income Statement Analysis – Financial Results
- Jay Bharat Maruti Limited (JAYBARMARU.NS) Income Statement Analysis – Financial Results
- PT Dyandra Media International Tbk (DYAN.JK) Income Statement Analysis – Financial Results
- Avantor, Inc. (AVTR) Income Statement Analysis – Financial Results
ShockWave Medical, Inc. (SWAV)
About ShockWave Medical, Inc.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 730.23M | 489.73M | 237.15M | 67.79M | 42.93M | 12.26M | 1.72M |
| Cost of Revenue | 95.39M | 65.00M | 41.44M | 20.99M | 17.16M | 7.25M | 2.84M |
| Gross Profit | 634.84M | 424.74M | 195.71M | 46.80M | 25.77M | 5.01M | -1.12M |
| Gross Profit Ratio | 86.94% | 86.73% | 82.53% | 69.03% | 60.03% | 40.88% | -64.98% |
| Research & Development | 145.65M | 81.68M | 50.54M | 36.93M | 32.85M | 22.70M | 17.96M |
| General & Administrative | 95.27M | 56.93M | 34.75M | 23.86M | 14.13M | 5.98M | 5.42M |
| Selling & Marketing | 234.84M | 162.00M | 111.29M | 51.67M | 30.62M | 17.54M | 6.36M |
| SG&A | 323.20M | 218.92M | 146.04M | 75.54M | 44.75M | 23.52M | 11.79M |
| Other Expenses | 23.96M | 1.06M | -582.00K | 1.26M | 2.35M | 589.00K | 366.00K |
| Operating Expenses | 468.85M | 300.60M | 196.58M | 112.46M | 77.61M | 46.21M | 29.75M |
| Cost & Expenses | 564.24M | 365.60M | 238.02M | 133.45M | 94.77M | 53.46M | 32.58M |
| Interest Income | 0.00 | 1.89M | 1.10M | 1.21M | 944.00K | 0.00 | 0.00 |
| Interest Expense | 6.20M | 1.89M | 1.10M | 1.21M | 944.00K | 401.00K | 58.00K |
| Depreciation & Amortization | 10.36M | -1.42M | -6.87M | 1.26M | 2.35M | 700.00K | 468.00K |
| EBITDA | 176.35M | 127.57M | -871.00K | -62.32M | -49.56M | -39.91M | -30.03M |
| EBITDA Ratio | 24.15% | 25.06% | -3.26% | -95.01% | -115.30% | -325.46% | -1,747.00% |
| Operating Income | 165.99M | 124.13M | -871.00K | -65.66M | -51.84M | -41.20M | -30.87M |
| Operating Income Ratio | 22.73% | 25.35% | -0.37% | -96.86% | -120.76% | -335.97% | -1,795.52% |
| Total Other Income/Expenses | 8.29M | -3.31M | -7.96M | 44.00K | 792.00K | 136.00K | 276.00K |
| Income Before Tax | 174.28M | 120.83M | -8.84M | -65.62M | -51.05M | -41.06M | -30.59M |
| Income Before Tax Ratio | 23.87% | 24.67% | -3.73% | -96.80% | -118.92% | -334.86% | -1,779.46% |
| Income Tax Expense | 27.00M | -95.17M | 301.00K | 80.00K | 62.00K | 38.00K | 26.00K |
| Net Income | 147.28M | 216.00M | -9.14M | -65.70M | -51.11M | -41.10M | -30.62M |
| Net Income Ratio | 20.17% | 44.10% | -3.85% | -96.92% | -119.06% | -335.17% | -1,780.98% |
| EPS | 4.01 | 6.02 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| EPS Diluted | 3.85 | 5.70 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| Weighted Avg Shares Out | 36.71M | 35.90M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
| Weighted Avg Shares Out (Dil) | 38.21M | 37.88M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
On April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, which is a 4.75% premium...
Acquisition Watch: Time to Buy Johnson & Johnson (JNJ) or ShockWave Medical's (SWAV) Stock?
News of healthcare behemoth Johnson & Johnson (JNJ) acquiring medical device company ShockWave Medical (SWAV) for $13.1 billion made headlines this morning.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.
NEW YORK, April 5, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Shockwave Medical, Inc. (NASDAQ: SWAV) and its board of directors concerning the proposed acquisition of the company by Johnson & Johnson (NYSE: JNJ)....
J&J Acquires Shockwave Medical to Boost Its Cardiovascular Treatment Portfolio
Johnson & Johnson (JNJ) announced Friday it was buying Shockwave Medical (SWAV) for $13.1 billion in cash, pushing shares of the maker of cardiovascular catheters to near all-time highs.
Johnson & Johnson to acquire medical device company Shockwave Medical for $13.1B
Johnson & Johnson (NYSE:JNJ) (J&J) will bolster its portfolio of medical devices targeting heart disease with its $13.1 billion acquisition of Shockwave Medical. The companies announced on Friday that J&J will acquire Shockwave for $335 per share in cash funded through...
Johnson & Johnson to acquire medical device company Shockwave Medical for $13.1B
Johnson & Johnson (NYSE:JNJ) (J&J) will bolster its portfolio of medical devices targeting heart disease with its $13.1 billion acquisition of Shockwave Medical. The companies announced on Friday that J&J will acquire Shockwave for $335 per share in cash funded through...
Shockwave Medical Stock Rises After Johnson & Johnson Buyout
Shockwave Medical Inc (NASDAQ:SWAV) is in the spotlight today, after blue-chip pharmaceutical giant Johnson & Johnson (JNJ) announced it would buy the company for $12.5 billion, boosting its portfolio of cardiovascular disease treatment devices.
Shareholder Alert: Ademi LLP investigates whether Shockwave Medical, Inc. has obtained a Fair Price in its transaction with Johnson & Johnson
MILWAUKEE, April 5, 2024 /PRNewswire/-- Ademi LLP is investigating Shockwave (Nasdaq: SWAV) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson. Click here to learn how to join the https://www.ademilaw.com/case/shockwave-medical-inc or call...
Johnson & Johnson to Buy Shockwave Medical in $13.1 Billion Deal
The healthcare giant said the addition of the medical-device maker would expand its MedTech cardiovascular portfolio.
Johnson & Johnson Buys Shockwave For $13.1 Billion In Latest Cardio Deal
Johnson & Johnson will acquire Shockwave Medical in a deal valued at $13.1 billion, according to a joint statement Friday, the latest acquisition by the pharmaceutical firm over the last two years as it expands on cardiovascular intervention.
Source: https://incomestatements.info
Category: Stock Reports